Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Life Sciences Industry Analysis

UpdatedJan 02, 2026
DataAggregated Company Financials
Companies22
  • 7D-1.7%
  • 3M0.5%
  • 1Y-3.6%
  • YTD0%

Over the last 7 days, the Life Sciences industry has dropped 1.7%, driven by Divi's Laboratories declining 0.5%. However, the industry is down 3.6% over the past year. As for the next few years, earnings are expected to grow by 22% per annum.

Industry Valuation and Performance

Has the Indian Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 03 Jan 2026₹3.1t₹342.6b₹48.4b34x64x9x
Mon, 01 Dec 2025₹3.1t₹342.6b₹48.4b33x64x9x
Wed, 29 Oct 2025₹3.2t₹331.4b₹45.5b44.4x70.3x9.6x
Fri, 26 Sep 2025₹3.1t₹331.4b₹45.5b46.7x68.8x9.4x
Sun, 24 Aug 2025₹3.2t₹331.4b₹45.5b40.9x70.6x9.7x
Tue, 22 Jul 2025₹3.3t₹319.5b₹41.7b53.8x79.4x10.4x
Thu, 19 Jun 2025₹2.8t₹299.7b₹37.2b46.7x76.5x9.5x
Sat, 17 May 2025₹2.7t₹294.5b₹32.8b49.8x82.7x9.2x
Mon, 14 Apr 2025₹2.5t₹287.4b₹30.8b43.3x80.3x8.6x
Wed, 12 Mar 2025₹2.5t₹287.4b₹30.8b48x80.1x8.6x
Fri, 07 Feb 2025₹2.7t₹286.4b₹31.3b46.6x86.4x9.4x
Sun, 05 Jan 2025₹2.6t₹269.1b₹30.1b55.4x85.9x9.6x
Tue, 03 Dec 2024₹2.5t₹254.2b₹28.8b54.4x87.4x9.9x
Thu, 31 Oct 2024₹2.4t₹247.9b₹26.0b49.4x91.5x9.6x
Sat, 28 Sep 2024₹2.3t₹247.6b₹26.3b49.6x86.7x9.2x
Mon, 26 Aug 2024₹2.1t₹247.1b₹23.8b38.2x87.9x8.5x
Wed, 24 Jul 2024₹1.8t₹201.9b₹23.9b37.5x75x8.9x
Fri, 21 Jun 2024₹1.7t₹194.5b₹21.5b33.8x81x9x
Sun, 19 May 2024₹1.6t₹193.9b₹21.6b34.7x73x8.1x
Tue, 16 Apr 2024₹1.4t₹168.5b₹18.6b29.1x76x8.4x
Thu, 14 Mar 2024₹1.3t₹168.5b₹18.6b28.2x70.8x7.8x
Sat, 10 Feb 2024₹1.4t₹167.1b₹19.0b33.1x74x8.4x
Mon, 08 Jan 2024₹1.5t₹155.9b₹18.1b23.8x80.8x9.4x
Wed, 06 Dec 2023₹1.4t₹155.9b₹18.1b22.5x76.2x8.8x
Fri, 03 Nov 2023₹1.2t₹156.0b₹19.8b23.4x63.2x8x
Sun, 01 Oct 2023₹1.4t₹154.7b₹19.7b26.4x71.8x9.1x
Tue, 29 Aug 2023₹1.4t₹154.7b₹19.7b27.4x69.3x8.8x
Thu, 27 Jul 2023₹1.4t₹156.5b₹23.0b30.9x59.6x8.8x
Sat, 24 Jun 2023₹1.3t₹157.2b₹23.0b28.5x56.2x8.2x
Mon, 22 May 2023₹1.2t₹160.8b₹22.9b32.9x51.6x7.3x
Wed, 19 Apr 2023₹1.2t₹159.5b₹28.4b33.5x42.1x7.5x
Fri, 17 Mar 2023₹1.1t₹159.5b₹28.4b31x37x6.6x
Sun, 12 Feb 2023₹1.1t₹159.6b₹28.5b34.2x37x6.6x
Tue, 10 Jan 2023₹1.2t₹164.9b₹34.5b30.7x36x7.5x
Price to Earnings Ratio

36x


Total Market Cap: ₹1.2tTotal Earnings: ₹34.5bTotal Revenue: ₹164.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Life Sciences Industry Price to Earnings3Y Average 70.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Indian Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 64.0x which is lower than its 3-year average PE of 70.4x.
  • The industry is trading close to its 3-year average PS ratio of 8.7x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 12% per year over the last three years.
  • Revenues for these companies have grown 28% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market0.36%
Healthcare-0.67%
Life Sciences-1.67%
Clinical Research and Equipment-1.67%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ONESOURCE OneSource Specialty Pharma₹1.80k3.4%
+₹6.7b		n/aPE507.3x
SAILIFE Sai Life Sciences₹921.702.8%
+₹5.3b		18.2%PE68x
SYNGENE Syngene International₹658.400.6%
+₹1.5b		-23.2%PE56x
INNOVACAP Innova Captab₹725.152.2%
+₹875.5m		-38.7%PE33.3x
DCAL Dishman Carbogen Amcis₹254.782.1%
+₹838.8m		-11.8%PE29.3x

Latest News

BROOKS
₹77.26
Brooks Laboratories
7D
-10.5%
1Y
-59.6%

Brooks Laboratories Limited (NSE:BROOKS) Not Doing Enough For Some Investors As Its Shares Slump 31%

Dec 31
Brooks Laboratories Limited (NSE:BROOKS) Not Doing Enough For Some Investors As Its Shares Slump 31%
DIVISLAB
₹6,392.50
Divi's Laboratories
7D
-0.5%
1Y
5.7%

Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)

Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
FABTECH
₹198.18
Fabtech Technologies
7D
-2.0%
1Y
n/a
511509
₹31.62
Vivo Bio Tech
7D
-3.0%
1Y
-24.8%
INDGN
₹522.55
Indegene
7D
0.4%
1Y
-12.4%

INDGN: Upcoming Board And Shareholder Actions Will Support Continued Positive Momentum

Narrative Update on Indegene Analysts have slightly reduced their price target on Indegene by approximately ₹2 to about ₹610, reflecting marginal adjustments to discount rate and profit margin assumptions, along with a modest increase in long term revenue growth expectations. What's in the News Indegene has expanded its Consulting Practice to provide integrated strategy and transformation support for life sciences clients, aiming to deliver both strategic insight and hands on implementation across the value chain (Key Developments).
524394
₹609.25
Vimta Labs
7D
-0.3%
1Y
28.8%
SAILIFE
₹921.70
Sai Life Sciences
7D
2.8%
1Y
18.2%

Is Sai Life Sciences (NSE:SAILIFE) A Risky Investment?

Dec 19
Is Sai Life Sciences (NSE:SAILIFE) A Risky Investment?
DCAL
₹254.78
Dishman Carbogen Amcis
7D
2.1%
1Y
-11.8%
AKUMS
₹451.85
Akums Drugs and Pharmaceuticals
7D
1.2%
1Y
-28.7%

AKUMS: Zambian Manufacturing Expansion Will Support Future Earnings And Margin Strength

Analysts have modestly revised their price target for Akums Drugs and Pharmaceuticals to ₹638.33 per share, reflecting slightly lower discount rate and future P/E assumptions while maintaining their outlook on revenue growth and profit margins. What's in the News The board has approved a USD 24 million (about INR 2,000 million) investment in subsidiary Akums Healthcare Zambia to establish a manufacturing facility and expand its presence in Zambia and neighboring African markets, with funding via equity and/or debt secured by MIGA insurance (Key Developments).
ONESOURCE
₹1,799.50
OneSource Specialty Pharma
7D
3.4%
1Y
n/a

A Look At The Intrinsic Value Of OneSource Specialty Pharma Limited (NSE:ONESOURCE)

Dec 15
A Look At The Intrinsic Value Of OneSource Specialty Pharma Limited (NSE:ONESOURCE)
INNOVACAP
₹725.15
Innova Captab
7D
2.2%
1Y
-38.7%

INNOVACAP: Stable Margins And Growth Outlook Will Drive Future Upside Potential

Analysts have maintained their price target for Innova Captab at ₹808.5 per share, noting that only minor adjustments to the discount rate and long term valuation assumptions were needed, based on stable growth and margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (company board filing).
SYNGENE
₹658.40
Syngene International
7D
0.6%
1Y
-23.2%

Some Shareholders Feeling Restless Over Syngene International Limited's (NSE:SYNGENE) P/E Ratio

Dec 09
Some Shareholders Feeling Restless Over Syngene International Limited's (NSE:SYNGENE) P/E Ratio
WINDLAS
₹788.90
Windlas Biotech
7D
-1.0%
1Y
-21.9%

Solid Earnings May Not Tell The Whole Story For Windlas Biotech (NSE:WINDLAS)

Nov 14
Solid Earnings May Not Tell The Whole Story For Windlas Biotech (NSE:WINDLAS)
530239
₹165.00
Suven Life Sciences
7D
-0.6%
1Y
28.2%
ANTHEM
₹654.45
Anthem Biosciences
7D
0.08%
1Y
n/a
539267
₹19.07
Samsrita Labs
7D
-8.9%
1Y
-16.1%